The new biopharmaceutical company AbbVie operates in Croatia, from June 1, as a result of spin-off from Abbott and took in his portfolio innovation and biologicals. A new company on the Croatian market has ten registered drugs, of which eight on the list of CIHI and has two percent of the market. AbbVie is globally established on 1 January this year, and the estimated value of 18 billion dollars. The company has streamlined and focused business model that provides $ 6 billion in cash flow.
AbbVie is a biopharmaceutical company founded to develop innovative medicines. In 2013 AbbVie will invest 14 percent of their income in clinical trials of new drugs.
AbbVie worldwide has 15 manufacturing plants and research and cooperate with many scientific Institution's and in Croatia with scientists from the Institute "Ruder Boskovic". Dr. Robert Vianello Institute pointed out that the synergy of science and industry is the right way to discover innovation in biotechnology.
